These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 18585544)

  • 1. Cabergoline-induced psychotic exacerbation in schizophrenic patients.
    Chang SC; Chen CH; Lu ML
    Gen Hosp Psychiatry; 2008; 30(4):378-80. PubMed ID: 18585544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
    Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
    Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
    J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiopulmonary complications of ergot-derivative dopamine agonists.
    Rack MJ; Baran AS; Richert AC; Roffwarg HP
    J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
    Cohen LG; Biederman J
    J Child Adolesc Psychopharmacol; 2001; 11(4):435-40. PubMed ID: 11838826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment].
    Pollice R; Di Giovambattista E; Tomassini A; Di Pucchio A; Mazza M; Di Michele V; Roncone R; Casacchia M
    Clin Ter; 2007; 158(2):121-6. PubMed ID: 17566512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
    Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
    J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics.
    Coronas R; Cobo J; Giménez-Palop O; Ortega E; Márquez M
    Curr Drug Saf; 2012 Apr; 7(2):92-8. PubMed ID: 22873493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
    Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
    Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
    Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
    BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia.
    Keller R; Mongini F
    Neurol Sci; 2002 Dec; 23(5):233-5. PubMed ID: 12522680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    Paulzen M; Gründer G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of symptomatic hyperprolactinemia by aripiprazole.
    Wahl R; Ostroff R
    Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.